Straits Times Index
3,147.46 +31.15 (+1.00%) Nikkei
26,425.70 +251.72 (+0.96%) Hang Seng
17,466.89 +216.01 (+1.25%) FTSE 100
7,005.39 +20.80 (+0.30%) BTC-USD
19,573.49 +815.49 (+4.35%) CMC Crypto 200
446.94 +18.16 (+4.24%)
Valneva SE (VALN)
- Zacks
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
- Business Wire
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
SAINT-HERBLAIN, France & CAMBRIDGE, Mass., September 08, 2022--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
- Business Wire
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
